WebFeb 1, 2024 · Objective: To summarize the cancer burden and trends in China, compare the differences among China, Japan, and South Korea and discuss possible causes of the disparities. Methods: Incidence and mortality data were extracted from the online cancer database including the GLOBOCAN 2024 and the Global Burden of Disease Study 2024. … WebVolume 36 February - December 2024. December 2024, issue 6. Special Column on Photocatalysis. October 2024, issue 5. August 2024, issue 4. Special Issue on Two-dimensional (2D) Materials. June 2024, issue 3. April 2024, issue 2. Special Issue on DNA Nanotechnology.
Evaluation and reflection on claudin 18.2 targeting therapy in …
http://article.cjcrcn.org/en/article/doi/10.21147/j.issn.1000-9604.2024.02.13?viewType=HTML WebChinese Journal of Cancer Research. Journal Abbreviation: CHINESE J CANCER RES. Journal ISSN: 1000-9604. Year. Impact Factor (IF) Total Articles. Total Cites. 2024 (2024 update) 4.026. tryhard agario names
Cancer incidence and mortality in China, 2016 - ScienceDirect
WebChinese Journal of Cancer Research Author Instruction Chinese Journal of Cancer Research (CJCR) is an international, peer ... et al. Cancer incidence and mortality in China, 2014. Chin J Cancer Res 2024;30:1-12. Chen WQ, Zheng RS, Zeng HM, et al. Trend analysis and projection … WebFeb 13, 2024 · Claudin 18.2 (CLDN18.2) is a tight-junction protein. CLDN18.2-targeting strategy has cut a striking figure in CLDN18.2 positive patients with advanced gastric cancer. Zolbetuximab, the CLDN18.2 antibody, obtained a better clinical benefit in patients compared with the controlled. In phase II trials, combination treatment of epirubicin, … http://article.cjcrcn.org/article/2024/2?pageType=en philizz video yearmix